Metabolic Collaboration and Licensing Deals 2019-2026

Key Benefits

✔ Benchmark against 649 metabolic partnering deals – Access a substantial body of real-world collaboration and licensing activity to identify relevant precedents and comparable transactions.

✔ Benchmark metabolic deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.

✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in metabolic assets, technologies, therapeutic indications, targets and relevant stages of development.

✔ Compare activity across the metabolic landscape – Analyze dealmaking by therapeutic indication and target, development stage, technology type, deal type, industry sector and company.

✔ Find the most relevant comparable transactions – Move beyond broad averages to identify deals involving similar indications, targets, technologies, development stages and partnering structures.

✔ Understand how metabolic deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.

✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.

✔ Apply the intelligence to your own metabolic opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, indication, target, technology, prospective partners or transaction objectives.

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in metabolic dealmaking

 

2.1. Introduction

2.2. Metabolic partnering over the years     

2.3. Metabolic partnering by deal type

2.4. Metabolic partnering by industry sector

2.5. Metabolic partnering by stage of development

2.6. Metabolic partnering by technology type

2.7. Metabolic partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for metabolic partnering

 

3.1. Introduction

3.2. Disclosed financials terms for metabolic partnering

3.3. Metabolic partnering headline values

3.4. Metabolic deal upfront payments

3.5. Metabolic deal milestone payments

3.6. Metabolic royalty rates

 

Chapter 4 – Leading metabolic deals and dealmakers

 

4.1. Introduction

4.2. Most active in metabolic partnering

4.3. List of most active dealmakers in metabolic    

4.4. Top metabolic deals by value

 

Chapter 5 – Metabolic contract document directory

                                            

5.1. Introduction

5.2. Metabolic partnering deals where contract document available

 

Chapter 6 – Metabolic dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by metabolic therapeutic target

 

Deal directory

 

Deal directory – Metabolic deals by company A-Z

Deal directory – Metabolic deals by technology type

 

Deal type definitions

 

About Biopharma Research Ltd

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Metabolic partnering since 2019

Figure 2: Metabolic partnering by deal type since 2019

Figure 3: Metabolic partnering by industry sector since 2019

Figure 4: Metabolic partnering by stage of development since 2019

Figure 5: Metabolic partnering by technology type since 2019

Figure 6: Metabolic partnering by indication since 2019

Figure 7: Metabolic deals with a headline value

Figure 8: Metabolic deals with upfront payment values

Figure 9: Metabolic deals with milestone payment

Figure 10: Metabolic deals with royalty rates

Figure 11: Active metabolic dealmaking activity since 2019

Figure 12: Top metabolic deals by value since 2019

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3DR Labs, 4P-Pharma, 23andMe, 180 Life Sciences, Abbisko Therapeutics, Abbott Laboratories, AbCellera Biologics, Abeona Therapeutics, AcelaBio, Acentrus Specialty, Acenzia, Aceragen, Ache, Acuitas Therapeutics, Adaptive Phage Therapeutics, Adhera Therapeutics, Advanz Pharma, AdventHealth, Aeglea BioTherapeutics, AEterna Zentaris, Aevi Genomic Medicine, AgeX Therapeutics, AiCuris, Ajinomoto, Akcea Therapeutics, Akero Therapeutics, Albert Einstein College of Medicine, Albireo, Alexion Pharmaceuticals, Alfasigma, Aligos Therapeutics, Alimentiv, AliveCor, Alkem Laboratories, Allele Biotechnology and Pharmaceuticals, AllerGenis, Allevi 3D, Almelo, Alnylam Pharmaceuticals, ALR Technologies, ALTuCELL, Alveus Therapeutics, Amarna Therapeutics, Amazentis, Ambiopharm, AM Chemicals, A Menarini Diagnostics, American Association for the Study of Liver Diseases, American Diabetes Association, Amgen, Amicus Therapeutics, AmideBio, AMMTeK, Amneal Pharmaceuticals, Amolyt Pharma, AMRA Medical, Amyris, Anagram Therapeutics, Angers University, Anji Pharma, Antares Pharma, Apellis Pharmaceuticals, Apollon Formularies, Apollo Therapeutics, Applied DNA Sciences, Applied Therapeutics, APR Applied Pharma Research, Arbor Biotechnologies, Arch Biopartners, Archer Daniels Midland Company, Arecor, Arecor Therapeutics, Argon Medical Devices, Arjuna Naturals, Arrowhead Pharmaceuticals, Arzeda, Ascendis Pharma, Ascensia Diabetes Care, Ascletis, Asklepios Biopharmaceutical, Aspect Biosystems, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, ATUM, Avicanna, Avrobio, Axcella, AXIM Biotechnologies, Axovant Gene Therapies, Baliopharm, Bavarian Brewing & Beverage Institute, Baxter International, Bayer, BCD Bioscience, Beam Therapeutics, Beijing University of Chinese Medicine, Bened Biomedical, Benuvia Therapeutics, Berg, Beta Bionics, Better Therapeutics, Beyond Type 1, Bigfoot Biomedical, Bill and Melinda Gates Foundation, Bioadaptives, biOasis Technologies, Biocon, BIOCORP, Biodexa Pharmaceuticals, BioHarvest Sciences, BIOHM Health Inc, BioLinQ, Biolojic Design, BioMed X Innovation Center, BioPep, Biosidus, Biosplice, Bird Foundation, Boehringer Ingelheim, Bond Pet Foods, Bonne Santé Group, Boston Scientific, BPGbio, Brand Institute, Bridge Biotherapeutics, Brigham and Women's Hospital, BrightInsight, Brightseed, Broad Institute, Bruker, Bruno Farmaceutici, Bunker Pflanzenextrakte, c-LEcta, Cambrooke Therapeutics, CamDiab, CAMP4 Therapeutics, Camurus, Can-Fite BioPharma, CANbridge Pharmaceuticals, Cantex Pharmaceuticals, Capillary Biomedical, Cardiff University, Cardinal Health, Cardiovascular Solutions of Central Mississippi, CASI Pharmaceuticals, Catalent, Cellarity, CELLINK, Celloram, Centene, Center for Genomic Regulation, Centogene, Centre for Commercialization of Regenerative Medicine (CCRM), Centrus Health Clinics, Century Therapeutics, Chemify, Chiasma, Chiesi Farmaceutici, Children's Hospital at Montefiore, Children's Hospital Boston, Chongqing Yao Pharmaceutical, ChromaDex, Cibus Global, Citrine Medicine, City of Hope, Civica Rx, CJ CheilJedang, Clarus Therapeutics, Clinigen, CN Bio, Code Biotherapeutics, Codexis, Columbia University, Companion Medical, Conatus Pharmaceuticals, Consilient Health, Cooper Aerobics, Corvium, Cosmos, COUR Pharmaceutical, Covance, Creative Medical Technologies, Crinetics, CRISPR Therapeutics, Critical Path Institute (C-Path), Crossject, CSPC Pharmaceutical Group, Cukierman & Co Life Sciences, Cure Genetics, Cycle Pharmaceuticals, Cyclo Therapeutics, CymaBay Therapeutics, Cystic Fibrosis Foundation, Cytoo, Dawn Health, Deargen, Decode Health, Deep Apple Therapeutics, Deerfield Management, Defense Health Agency (US), DEKA Research and Development, Delta 4, Delve Health, Department of Veterans Affairs, Dewpoint Therapeutics, DexCom, Diabeloop, Diabetes Research Connection, Diabetes Research Institute, Diabetes Singapore, Diamyd Medical, Dicerna Pharmaceuticals, DigiLab, Diomics, Diurnal, DKSH, DNAnexus, DolCas Biotech, Dong-A ST, DoveTree Medicines, DreaMed Diabetes, DSM, Duke Clinical Research Institute (DCRI), Duke University, DuPont Pharmaceuticals, Dyadic International, Dyno Therapeutics, EatLove, Eccogene, Echosens, EffRx Pharmaceuticals, eGenesis, Ei.Ventures, EirGen Pharma, Elcelyx Therapeutics, Eledon Pharmaceuticals, Eleven Biotherapeutics, Eli Lilly, ELNA Medical, Elo Life Systems, Emmyon, Enable Biosciences, ENDRA Life Sciences, Engitix, Engrail Therapeutics, Enogenesis, Entera Bio, Enzolytics, Enzyvant Science, Epitomee Medical, Er-Kim, Eracal Therapeutics, Eton Pharmaceuticals, European Union Regional Development Fund, European Wellness Biomedical Group, EVA Pharma, EverlyWell, Eversana, EVerZom, Evgen Pharma, Evidation Health, Evo Foods, EVOQ Therapeutics, Evotec, Evozyne, Ewopharma, ExCEEd Orphan, Fermbox Bio, First Wave Bio, FitBit, Flagship Biosciences, Fondazione San Raffaele, Fondazione Telethon, Fonterra, Food and Drug Administration (FDA), Fosun Pharmaceutical, Foundation for Diabetes Research, FUJIFILM Cellular Dynamics, Fundacion Progreso y Salud, G3 Therapeutics, G42 Healthcare, Gain Therapeutics, Galapagos, Galectin Therapeutics, Galmed Pharmaceuticals, Gan & Lee, Gannex Pharma, Gastrologix, GATC Health, GC Pharma, GE Healthcare, GEMMA Biotherapeutics, Genentech, General Automation Lab Technologies, Generation Bio, Generex Biotechnology, Genethon, Genevant Sciences, Genfit, Genome Quebec, Genomma Lab Internacional, Genprex, Gensaic, Gensci, George Clinical, Gilead Sciences, Ginkgo BioWorks, Glenmark Pharmaceuticals, Global Liver Institute, Glooko, GlucoModicum, Glympse Bio, Glytec, Goldfinch Bio, GoodRx, Graviton Bioscience, Group K Diagnostics, GSK, Halberd, Hamilton Company, Hanmi Pharmaceutical, Hansa Biopharma, Harvard Medical School, Haselmeier, Hatch Medical, HAYA Therapeutics, Health2Sync, Healthimation, Health Network Laboratories, Healthy.io, Healthy Grain, HemoShear, Hepalys Pharma, HepaTx, Hepion Pharmaceuticals, HepQuant, Hill's Pet Nutrition, HistoIndex, HitGen, HK inno.N, Horizon Discovery, Horizon Therapeutics, Humacyte, Hygieia, I-mab, i-SENS, iECURE, Imagine Pharmaceuticals, Imaware, Immedica, Immusoft, Immuthera, Imperial College London, Indiana University, Ingredion, Innovate UK, Innovation Zed, Innovent Biologics, Inserm, Insilico Medicine, Insitro, InSphero, Institute of Endocrinology, Metabolism, and Reproduction, Institut National Recherche Agronomique, Insulet, Intact Therapeutics, Integral Molecular, InterAx Biotech, Intercept Pharmaceuticals, International Diabetes Federation (IDF), International Niemann-Pick Disease Registry, Inventiva, Invitae, Ionis Pharmaceuticals, Ipsen, IQVIA, Ironwood Pharmaceuticals, iSage Rx, Itochu, iTolerance, Jackson Laboratory, Jadeite Medicines, Janssen Pharmaceuticals, Janssen Research & Development, Janssen Therapeutics, Jasper Therapeutics, JCR Pharmaceuticals, Jennewein Biotechnologie, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jinggangshan University, Johns Hopkins Medicine (JHM), Johns Hopkins University, Journey Medical, Jugular, Jumpcan Pharmaceutical, Juntendo University, Juvena Therapeutics, Juvenescence, Juvenile Diabetes Research Foundation, Kadimastem, Kahn-Sagol-Maccabi, Kaken Pharmaceutical, Kaleido Biosciences, Kalsec, Katana Pharmaceuticals, KeyBioScience, Klue, Know Labs, Kore, Korro Bio, Kyowa Hakko Kirin, Labcyte, Laboratory Corporation of America, Lannett, Lark Technologies, Launch Therapeutics, Leona M and Harry B Helmsley Charitable Trust, Lexicon Pharmaceuticals, LG Life Sciences, LifeOmic, LifeScan, Lipigon Pharmaceuticals, Lipocine, Livongo Health, LogicBio Therapeutics, Lonza, LUCA Science, Lumen Biomedical, Luminex, Lumos Pharma, Lurie Children's Hospital of Chicago, LyGenesis, Lygos, LY Research, Lysando, Lysogene, mAbXience, Madrigal Pharmaceuticals, Mammoth Biosciences, Mandos, MannKind Biopharmaceuticals, Martin Pharmaceuticals, Massachusetts General Hospital, Massachusetts Institute of Technology, Mass General Brigham, Max Biopharma, Mayo Clinic, Maze Therapeutics, McGill University, McQuade Center for Strategic Research and Development, Meatable, MEDIAN Technologies, Medical College of Wisconsin, Medical University of South Carolina, MediciNova, Medicox, MedImmune, Medipal Holdings, Medisca, Medison Pharma, Medtronic, Meitheal Pharmaceuticals, Melior Pharmaceuticals, Merck and Co, Merck KGaA, Merieux NutriSciences, Merz, Mesh Bio, Metaba, Meta Healthcare, MetaSight Diagnostics, Metro Health, Metsera, MiNA Therapeutics, Minerva Foods, Minovia Therapeutics, Miromatrix Medical, Mirum Pharmaceuticals, Mission Bio, Mitobridge, Mitsubishi Tanabe Pharma, MJH Life Sciences, Moderna, ModeX Therapeutics, Modular Medical, Mount Sinai Health System, mPulse Mobile, MRM Health, MThera Pharma, MultiOmic Health, Murdoch University, MyBiotics Pharma, MySugarWatch DuoPack, Namocell, NAMUH, Nano-X Imaging, NanoVation Therapeutics, NASH Network, National Cerebral and Cardiovascular Disease Research Center, National Heart, Lung and Blood Institute, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Child Health and Human Development, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, National Organization for Rare Disorders, National Research Council Canada, National University of Singapore, Navidea Biopharmaceuticals, Nebraska Medicine, Nemaura Medical, Nemysis, Neogen, Neo Gene Pharm, Neomorph, NephroDI Therapeutics, Nestle Health Science, Neuraxpharm, NeuroBiogen, NeuroBo Pharmaceuticals, Neurocrine Biosciences, Neurodon, NeuroFront, Newsoara Biopharma, New Wave Ventures, Neximmune, NGM Biopharmaceuticals, Nicoya, Nimbus Therapeutics, NIMIUM Therapeutics, NLC Pharma, Norgine, Northwestern University, NorthX Biologics, Novaremed, Novartis, Novasep, Novitium Pharma, Novo Integrated Sciences, Novo Nordisk, Nuformix, Numares, NutraFuels, Nutrition21, Ocean Spray Cranberries, Ochre Bio, Ohio State University, Okava Pharmaceuticals, OliX Pharmaceuticals, Omega Therapeutics, OmniaBio, One World Products, Ono Pharmaceutical, Onward Therapeutics, Open Book Extracts, OPKO Biologics, OPKO Health, Optithera, Optomed, Oramed Pharmaceuticals, Orchard Therapeutics, Oregon Health Sciences University, OrganOx, Orgenesis, OrphanPacific, OrsoBio, OSE Immunotherapeutics, OSI Pharmaceuticals, Oslo University Hospital, OTR Therapeutics, Otsuka, Ovation, Oxford Biomedica Solutions, Pancryos, Pandion Therapeutics, Paraza Pharma, Particles for Humanity, Parvus Therapeutics, Passage Bio, PathAI, Pathalys Pharma, Patia, Penn State Microbiome Center, PeptiDream, Performance Inspired Nutrition, PerkinElmer, Perspectum Diagnostics, Pfizer, PharmaCyte Biotech, Pharmanest, Pharmanovia, Pharmathen, Pharmavite, Phenex, Phillips-Medisize, PhoreMost, Photys Therapeutics, Phytolon, Piramal, Pliant Therapeutics, Pluristem Therapeutics, Pluristyx, Polyganics, Population Health Partners, PRA Health Sciences, Precision Diabetes, Premier Inc, Pressure BioSciences, ProBioGen, Processa Pharmaceuticals, Procyon Technologies, Profil Institute for Clinical Research, ProLynx, Promethera Biosciences, ProPath, Provention Bio, Psyence Therapeutics, Pulmatrix, Purnovate, Qilu Pharmaceutical, Quell Therapeutics, Quest Diagnostics, Radius Health, Rallybio, Rare Disease Company Coalition, Raziel Therapeutics, RC2, Readout Health, Reata Pharmaceuticals, Recordati, Redox, Redwire, Regeneron Pharmaceuticals, Regenxbio, Regional Cancer Institute of Montpellier, Regor Therapeutics, Relation Therapeutics, Relief Therapeutics, Remedium Bio, RenalytixAI, Renown Institute for Health Innovation, Replicate Bioscience, Resolution Therapeutics, Revive Therapeutics, Reyon Pharmaceuticals, Rezolute, Rho, Rimidi, Ripe Technology, Roche, Roche Diagnostics, RTW Investments, SafeTraces, Sagimet Biosciences, Salipro Biotech, Salix Pharmaceuticals, Sanacor, Sandhill One, SanegeneBio, Sanofi, Sanofi US Services, Sanwa Kagaku Kenkyusho, Science 37, Scientific Research Council, Scilex Holding, Scivita Medical Technology, Sciwind Biosciences, SCM Pharma, Seal Rock Therapeutics, Second Genome, Selecta Biosciences, Senda Biosciences, Senseonics, Senti Biosciences, Sentynl Therapeutics, Seoul National University, Septerna, Sequel Med Tech, Seraxis, Sernova, SFC Fluidics, Shanghai Jiao Tong University, Shenzhen Chipscreen Biosciences, Shionogi Pharma, Sichuan Deebio Pharmaceutical, Siemens Healthineers, Sigilon Therapeutics, Silence Therapeutics, Singapore General Hospital, Sino Biopharmaceutical, Sinopia Biosciences, Sirion Biotech, Sirona Biochem, SocialDiabetes, Societal CDMO, Solarea Bio, SomaLogic, Sonnet BioTherapeutics, SOOIL Development Company, Sookmyung Women's University, Sosei, Spark Therapeutics, Sparrow Pharmaceuticals, SPC Korea, Stealth BioTherapeutics, Steno Diabetes Center, SteroTherapeutics, Stevanato, Structure Therapeutics, Sumitomo Dainippon Pharma, Summit Clinical Research, Sun Genomics, Sunshine Lake Pharma, Surrozen, Suzhou Ribo Life Science, Suzhou Ribo Life Sciences, Synbiotech, Synbiotic Health, SynerK, Syneron Bio, Synlogic, Synspira, Synthetic Biologics, T-Cell Protect Hellas, Taisho Pharmaceutical, TaiwanJ Pharmaceuticals, Takara Bio, Takeda Pharmaceutical, Tandem Diabetes Care, Target RWE, Tate & Lyle, Taysha Gene Therapies, Technomark Life Sciences, Teijin, Terns Pharmaceuticals, Terumo, TeselaGen, Tespo, Tetra Bio-Pharma, Tetris Pharma, Texas A&M University, The Healthy Aging Company, Theracell, TheracosBio, The United Laboratories, Thorne HealthTech, Tianjin JuveStar Biotech, Tiburio Therapeutics, Tidepool, Tnuva Group, Todos Medical, Tome Biosciences, Tonghua Dongbao Pharma, TONIX Pharmaceuticals, Torrent Pharmaceuticals, Tottori University, TPMENA, TransThera, TransThera Sciences, TreeFrog Therapeutics, Trovita Health Science, True Diagnostics, TRx Biosciences, Twinlab, Twist Bioscience, UK Biobank, Ultragenyx Pharmaceuticals, Undisclosed Company, Universe Pharmaceuticals, University Hospitals Accountable Care Organization, University Libre of Brussels, University of Alberta, University of British Columbia, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Colorado, University of Edinburgh, University of Florida, University of Geneva, University of Maryland School of Medicine, University of Massachusetts, University of Miami, University of Michigan, University of Nebraska, University of New Mexico, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Sheffield, University of Technology Sydney, University of Texas, University of Toronto, University of Virginia, University of Washington, University of West Indies, University of Wisconsin-Madison, University Paris Diderot, UP International, Upsher-Smith, USANA Health Science, UW Medicine, Valbiotis, Valley Oils Partners, Valo Health, Vanderbilt University, Variant Bio, VELL Health, Ventus Therapeutics, Verantos, Veravas, Verdiva Bio, Versiti Blood Research Institute, Vertex Pharmaceuticals, Verve Therapeutics, VGI Health Technology, ViaCyte, Vifor Pharma, Viome, Vipergen, VIPUN Medical, Viralgen, Vir Biotechnology, Virginia Commonwealth University, Virginia Tech, Virtual Health Partners, VisionQuest Biomedical, Visirna Therapeutics, VistaGen Therapeutics, Vitro Biopharma, Vivani Medical, Vivet Therapeutics, Vivici, Vivtex, VOTIS Subdermal Imaging Technologies, vTv Therapeutics, Wake Forest University, Wake Forest University School of Medicine, Wanbang Biopharmaceuticals, Washington University in St Louis, WaVe Lifesciences, Weizmann Institute, WellDoc, WellGen, Willow Biosciences, Winhealth Pharma Group, W L Gore, Worldwide Clinical Trials, Wuhan General Group, XERIS Pharmaceuticals, Xlife Sciences, Xoma, XtalPi, Yale University, Yarrow Bioscience, Yeda Research and Development Company, Yili Industrial Group, Ymir Genomics, Ypsomed, Yuhan Corporation, Zag Bio, Zealand Pharma, Zelira Therapeutics, Zhejiang Hisun Pharmaceutical, Zifo, ZyVersa Therapeutics

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

---

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

---

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

---

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

---

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

---

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

---

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

---

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

---

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.